Remember this “English alphabet” compiled from protein structures? I think Generate:Biomedicines nailed its marketing.
@generate_biomed ->IPO
04.03.2026 22:31
👍 0
🔁 0
💬 0
📌 0
Remember this “English alphabet” compiled from protein structures? I think Generate:Biomedicines nailed its marketing.
@generate_biomed ->IPO
Genomics is expanding from reading and editing DNA to reconstructing and writing it at scale
For a bird's eye overview of this rapidly evolving field, read the new deep dive by BiopharmaTrend: www.techlifesci.com/p/five-geno...
Cost and throughput keep dropping, making billion-cell screens/multi-omic atlases/population-scale programs economically plausible, and pushing competition toward reads-per-run/dollars-per-genome.
Reproductive genomics is sliding from embryo screening toward embryo ranking
Personalized gene editing is drifting from “one therapy for many” toward modular platforms
Perturb-Seq data is turning into industrial, reusable infrastructure
Genomics affects so many applied areas of drug discovery, biotech, and other things that it is hard to compare to anything else.
Five takeaways & predictions for genomics in 2026:
In science and tech, where the stakes are "change the world or go bust," a founder needs a story that doesn't sound like it was hallucinated by a chatbot.
How Billionaires Die?
There is a new study, and you will probably be surprised by the results…
medium.com/@editor_243...
I wrote a longer piece looking at the institutional and economic implications of this shift — how a metabolic drug class moved from diabetes clinics to trillion-dollar valuations and policy debates.
If interested, here it is:
medium.com/@editor_243...
At recent scientific meetings, I noticed another shift in framing.
Researchers are increasingly discussing GLP-1 drugs in the context of long-term disease delay, as tools that may influence how populations age by reducing major metabolic risks.
That is still being studied...
GLP-1 drugs — such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — were originally developed for type 2 diabetes.
They mimic a gut hormone involved in appetite and insulin regulation.
What surprised many observers was the scale of their broader impact.
Eli Lilly recently became the first pharmaceutical company in history to cross a $1 trillion market valuation.
The main driver wasn’t oncology or gene therapy.
It was a class of metabolic drugs known as GLP-1 receptor agonists.
When applied in the real world, it increased output materially.
All in all, AI in pharma isn’t an “easy button” for discovery timelines.
But in structured, repeatable environments like manufacturing and operations, it is already generating real operational and revenue impact.
3. Digital twins in production
Lilly created a digital twin of a critical manufacturing step for a GLP-1 drug, modeling equipment, process inputs, temperature behavior, and performance variables. After running large-scale simulations, outperformed the original setup.
2. Demand forecasting and supply chain optimization
Pharma supply chains are complex and highly sensitive to demand swings. Machine learning models analyze patterns across production, logistics, and market signals to predict demand more accurately than traditional planning.
1. Manufacturing quality control
Lilly uses AI-driven computer vision to take 70–80 images of every autoinjector in milliseconds. The system checks for microscopic defects at a speed and consistency humans can’t match. That directly improves product safety, reduces waste.
What is more interesting is where AI is already delivering measurable results, according to Diogo:
But in a new interview for MedCityNews, Diogo Rau clarified that AI is not going to turn 10-year development cycles into 2-year breakthroughs. Even if you optimize everything computationally, biology still takes time. Clinical validation still takes time...
Here are 3 real-life AI uses beyond the drug discovery hype, according to Diogo Rau, CIDO at Eli Lilly.
With Lilly announcing a $1B AI innovation lab with Nvidia, most headlines focused on AI-powered drug discovery.
The one career move that gave me more leverage than my PhD...
medium.com/@editor_243...
Longevity isn't just about fixing bodies.
It's about managing ecosystems, biological, microbial, and institutional.
Because we aren’t just bodies moving through time.
We’re environments embedded in bigger ones...
Read to delve deeper: www.moleculesempires.com/p/a-thought...
Some societies will design systems that protect and support this balance.
Others won’t.
And over time, that difference might quietly decide who gets to age well — and who doesn’t.
Zoom out and the story shifts.
Aging isn’t just personal decay.
It’s shaped by how well our inner ecosystems hold up against stress, infection, imbalance.
And how society chooses to manage that complexity.
Why this matters:
If aging is ecological, the solution isn’t just pills and surgeries.
It’s:
— Better diets
— Microbiome-safe drugs
— Public health that supports immune resilience
— Even new delivery systems like nasal sprays targeting the brain-gut axis
Cancer researchers already know:
Patients on antibiotics often respond worse to immunotherapy.
Some even recover after a fecal microbiota transplant (yes, seriously).
Your microbiome can make or break cutting-edge treatment.
Cancer researchers already know:
Patients on antibiotics often respond worse to immunotherapy.
Some even recover after a fecal microbiota transplant (yes, seriously).
Your microbiome can make or break cutting-edge treatment.
Cancer researchers already know:
Patients on antibiotics often respond worse to immunotherapy.
Some even recover after a fecal microbiota transplant (yes, seriously).
Your microbiome can make or break cutting-edge treatment.
Cancer researchers already know:
Patients on antibiotics often respond worse to immunotherapy.
Some even recover after a fecal microbiota transplant (yes, seriously).
Your microbiome can make or break cutting-edge treatment.
A CEO of Maxwell Biosciences, a cutting-edge biotech in the antimicrobial space, put it bluntly:
“Aging should be treated as a communicable disease.”
Why?
Because persistent pathogens + imbalanced microbiomes don’t just accompany aging…
They drive it.